Thrombin inhibitor
US-9217027-B2 · Dec 22, 2015 · US
US2016296647A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016296647-A1 |
| Application number | US-201615180587-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 13, 2016 |
| Priority date | Jul 15, 2010 |
| Publication date | Oct 13, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods are provided that better describe, and localize the pain generator or suspected pain generator in and around spinal discs in relation to neck or back pain so as to improve the diagnosis of degenerative disc disease. In some embodiments, there are methods for diagnosing a pain generator or a suspected pain generator in a patient suffering from back pain, the methods comprise labeling an inflammatory, vascular, neuronal, and/or metabolic pain marker at a location inside of or adjacent to an intervertebral disc in the patient suffering from back pain to increase an image of the pain marker with an imaging procedure; and imaging the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker in a manner sufficient to diagnose the pain generator or suspected pain generator.
Opening claim text (preview).
1 . A method for diagnosing a pain generator or a suspected pain generator in a patient suffering from neck or back pain, the method comprising labeling an inflammatory, vascular, neuronal, and/or metabolic pain marker at a location inside of or adjacent to an intervertebral disc in the patient suffering from back pain, allowing the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker to bind the pain generator or suspected pain generator; and imaging the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker bound to the pain generator or suspected pain generator in a manner sufficient to diagnose the pain generator or suspected pain generator. 2 . (canceled) 3 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises at least one muscle, ligament, tendon, cartilage, nerve, spinal disc, spinal foraminal space near the spinal nerve root, facet or spinal canal. 4 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises a substance associated with a nerve fiber or a cellular structure associated with the nerve fiber. 5 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises an inflammatory or proinflammatory factor. 6 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises a leukocyte. 7 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises a cytokine. 8 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises nerve growth factor, vascular endothelial growth factor, IL-1, IL-6, or IL-8. 9 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker is labeled by an antibody that binds the pain generator or suspected pain generator. 10 . A method according to claim 1 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises [18F] FDG (2′-deoxy-2′-fluro-D-glucose) or [18F] 1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl) piperidine or [18F] AH-111585. 11 . A method for diagnosing a pain generator or a suspected pain generator in a patient suffering from degenerative disc disease, the method comprising determining an amount of labeled inflammatory, vascular, neuronal, and/or metabolic pain marker in a location inside of or adjacent to an intervertebral disc in the patient suffering from degenerative disc disease; and comparing the amount of labeled inflammatory, vascular, neuronal, and/or metabolic pain marker in a location inside of or adjacent to an intervertebral disc to a normal range of the labeled pain marker inside of or adjacent to an intervertebral disc, wherein the amount of the labeled pain marker outside of the normal range indicates the location of the pain generator or suspected pain generator. 12 . (canceled) 13 . (canceled) 14 . A method according to claim 11 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker is associated with a nerve fiber or a cellular structure associated with the nerve fiber. 15 . A method according to claim 11 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises an inflammatory factor. 16 . A method according to claim 11 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises a leukocyte. 17 . A method for diagnosing a pain generator or a suspected pain generator in a patient suffering from neck or back pain, the method comprising administering a diagnostic agent that specifically binds to an inflammatory, vascular, neuronal, and/or metabolic pain marker at a location inside of or adjacent to an intervertebral disc in the patient suffering from back pain; allowing the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker to specifically bind to the pain generator or suspected pain generator; and imaging the bound labeled inflammatory, vascular, neuronal, and/or metabolic pain marker in a manner sufficient to diagnose the pain generator or suspected pain generator. 18 . A method according to claim 17 , wherein the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker comprises 18F FDG (2′-deoxy-2′-fluro-D-glucose) or 18F 1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl) piperidine or [18F] AH-111585. 19 . A method according to claim 17 , wherein the diagnostic agent is administered by intravenous, intramuscular, intrathecal, subcutaneous, epidural, intra-discal, peridiscal, peridural, perispinal administration or a combination thereof. 20 . (canceled)
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
having six-membered rings with one nitrogen as the only ring hetero atom · CPC title
Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers · CPC title
for diagnosis of nerves · CPC title
for contrast media · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.